DEERFIELD MANAGEMENT COMPANY, L.P.
New York, NY · CIK 1009258 · 13F filing filed 2022-08-15
SEC-registered investment adviser since 2012 · limited partnership
- Assets managed$19.1bn
- Staff189 · 89 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds12 (11 hedge) · $19.2bn gross assets
- Form ADV · 2026-07-31SEC adviser record
- Legal entityDEERFIELD MANAGEMENT COMPANY, L.P. (US)
- Kindhedge funds, private equity, futures
- Others nearbyNew York, NY, Parsippany, NJ
As an employer
- Offices in1 country
- Private fundshedge 11, private equity 1
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| New York, NY (main office)United States | about 86 |
| Parsippany, NJUnited States | 3 |
US visa salary filings
- Filings FY2024–20266
- Median salary offered$160,000
- Middle half$140,000 – $191,250
- Job titles5
| Job title | Filings | Median |
|---|---|---|
| AnalystNew York, NY | 2 | $140,000 |
| Data EngineerNew York, NY | 1 | $210,000 |
| Senior Director, Business IntelligenceNew York, NY | 1 | $195,000 |
| Director, Business IntelligenceNew York, NY | 1 | $180,000 |
| Market Research AssociateNew York, NY | 1 | $80,000 |
Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Deerfield Management Company, L.P..
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
Options: 1 call positions ($102.0m notional), 0 put positions (— notional) – listed below, not included above.
This report includes the holdings of 1 other manager that shares the investment decisions:
- Flynn Management LLC – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| GLAUKOS CORP GKOS 2.75 06.15.27 · principal | $324.5m6.84% | Added +1.9m |
| NUVALENT INC COM | $262.3m5.53% | Unchanged |
| VIATRIS INC VTRS | $216.5m4.56% | Unchanged |
| ADAPTHEALTH CORP AHCO | $201.2m4.24% | Reduced -499.3k |
| NEUROCRINE BIOSCIENCES INC NBIX | $196.2m4.13% | Added +354.9k |
| INVITAE CORP NVTA 2 09.01.24 · principal | $163.0m3.43% | Unchanged |
| AERIE PHARMACEUTICALS INC AERI 1.5 10.01.24 · principal | $133.0m2.80% | Unchanged |
| IONIS PHARMACEUTICALS INC IONS 0 04.01.26 · principal | $117.0m2.46% | New |
| NATERA INC NTRA 2.25 05.01.27 · principal | $111.9m2.36% | Unchanged |
| SAREPTA THERAPEUTICS INC SRPT 1.5 11.15.24 | $111.8m2.35% | Unchanged |
| ENVISTA HOLDINGS CORPORATION NVST 2.375 06.01.25 · principal | $100.4m2.11% | Unchanged |
| SILK RD MED INC SILK | $97.4m2.05% | Added +523.2k |
| TABULA RASA HEALTHCARE INC TRHC 1.75 02.15.26 · principal | $97.2m2.05% | Added +36.7m |
| GILEAD SCIENCES INC GILD | $96.0m2.02% | Added +787.1k |
| NUVASIVE INC GMED 1 06.01.23 · principal | $93.6m1.97% | Unchanged |
| PACIRA BIOSCIENCES INC PCRX 0.75 08.01.25 · principal | $85.0m1.79% | Unchanged |
| DECIPHERA PHARMACEUTICALS IN DCPH | $82.2m1.73% | Added +670.5k |
| APELLIS PHARMACEUTICALS INC APLS 3.5 09.15.26 · principal | $76.5m1.61% | Unchanged |
| NUVASIVE INC GMED 0.375 03.15.25 · principal | $71.7m1.51% | Unchanged |
| INSMED INC INSM 1.75 01.15.25 · principal | $70.5m1.48% | Unchanged |
| IMMUNOGEN INC IMGN | $67.6m1.42% | Added +11.5m |
| INSULET CORP PODD 0.375 09.01.26 · principal | $66.0m1.39% | Unchanged |
| MIRUM PHARMACEUTICALS INC MIRM | $63.1m1.33% | Reduced -38.5k |
| DAY ONE BIOPHARMACEUTICALS I COM | $62.9m1.32% | Added +1.4m |
| ACCOLADE INC ACCD 0.5 04.01.26 · principal | $59.1m1.25% | New |
| NEVRO CORP NVRO 2.75 04.01.25 · principal | $57.7m1.22% | Unchanged |
| CAREMAX INC COM CL A | $57.6m1.21% | Unchanged |
| GUARDANT HEALTH INC GH 0 11.15.27 · principal | $56.7m1.19% | New |
| INTERCEPT PHARMACEUTICALS IN ICPT 3.25 07.01.23 · principal | $56.2m1.18% | Unchanged |
| COGENT BIOSCIENCES INC COGT | $53.0m1.12% | Added +4.3m |
| PULMONX CORP LUNG | $51.0m1.07% | Reduced -229.4k |
| IVERIC BIO INC OPHT | $50.2m1.06% | Added +322.0k |
| CENTENE CORP DEL CNC | $49.0m1.03% | Added +25.0k |
| OAK STR HEALTH INC OSH 0 03.15.26 | $48.6m1.02% | New |
| KURA ONCOLOGY INC KURA | $48.2m1.01% | Reduced -1.8m |
| GLAUKOS CORP GKOS | $47.2m0.99% | Added +670.0k |
| MOLINA HEALTHCARE INC MOH | $46.7m0.98% | Added +32.0k |
| CYTOKINETICS INC CYTK | $45.6m0.96% | Added +207.6k |
| MERUS N V MRUS | $45.0m0.95% | Added +1.5m |
| DYNAVAX TECHNOLOGIES CORP DVAX 2.5 05.15.26 · principal | $44.7m0.94% | New |
| LIVONGO HEALTH INC TDOC 0.875 06.01.25 · principal | $42.4m0.89% | New |
| EVOLUS INC EOLS | $42.1m0.89% | Added +2.4m |
| 1LIFE HEALTHCARE INC ONEM 3 06.15.25 · principal | $40.2m0.85% | Added +8.6m |
| BROOKDALE SR LIVING INC BKD | $39.0m0.82% | Added +3.2m |
| AERIE PHARMACEUTICALS INC AERI | $35.2m0.74% | Unchanged |
| PTC THERAPEUTICS INC PTCT 1.5 09.15.26 · principal | $33.4m0.70% | New |
| EDGEWISE THERAPEUTICS INC EWTX | $31.3m0.66% | Unchanged |
| HILLEVAX INC COM | $28.6m0.60% | New |
| PHARVARIS N V PHVS | $26.3m0.55% | Reduced -386.7k |
| PTC THERAPEUTICS INC PTCT 3 08.15.22 · principal | $25.5m0.54% | Added +10.9m |
| HORIZON THERAPEUTICS PUB L HZNP | $25.0m0.53% | Reduced -152.0k |
| NOVAVAX INC NVAX 3.75 02.01.23 · principal | $24.9m0.52% | Unchanged |
| SINGULAR GENOMICS SYSTEMS IN COM | $24.2m0.51% | Reduced -275.7k |
| SEMA4 HOLDINGS CORP SMFR | $23.7m0.50% | Added +5.0m |
| BELLUS HEALTH INC NEW BLU | $22.9m0.48% | Reduced -1.2m |
| ORGANOGENESIS HLDGS INC ORGO | $21.7m0.46% | Reduced -4.0m |
| PHREESIA INC PHR | $21.4m0.45% | New |
| SYNDAX PHARMACEUTICALS INC SNDX | $21.4m0.45% | New |
| AMEDISYS INC AMED | $20.9m0.44% | New |
| TARSUS PHARMACEUTICALS INC TARS | $19.3m0.41% | New |
| INSMED INC INSM | $18.9m0.40% | Added +655.9k |
| XERIS PHARMACEUTICALS INC XERS 5 07.15.25 · principal | $17.6m0.37% | Unchanged |
| REVOLUTION MEDICINES INC RVMD | $17.4m0.37% | Unchanged |
| THE ONCOLOGY INSTITUTE INC STLN | $17.1m0.36% | Added +87.0k |
| PACIRA BIOSCIENCES INC PCRX | $17.0m0.36% | New |
| ALPHATEC HLDGS INC ATEC | $15.8m0.33% | Reduced -1.2m |
| ANAPTYSBIO INC ANAB | $15.7m0.33% | New |
| DA32 LIFE SCNCE TEC ACQSTN C CLASS A COM | $15.5m0.33% | Unchanged |
| HEALTH CATALYST INC HCAT 2.5 04.15.25 · principal | $13.5m0.28% | Unchanged |
| INOZYME PHARMA INC COM | $12.9m0.27% | Added +351.6k |
| PROFOUND MED CORP PROF | $12.5m0.26% | Unchanged |
| KEZAR LIFE SCIENCES INC COM | $11.7m0.25% | New |
| LARIMAR THERAPEUTICS INC LRMR | $11.4m0.24% | Unchanged |
| TG THERAPEUTICS INC TGTX | $11.4m0.24% | New |
| ALECTOR INC ALEC | $10.7m0.23% | Unchanged |
| FOGHORN THERAPEUTICS INC FHTX | $10.6m0.22% | Added +538.7k |
| EUCRATES BIOMEDICAL ACQU COR SHS | $9.9m0.21% | Unchanged |
| SARISSA CAPITAL ACQUISITN CO CL A | $9.9m0.21% | Unchanged |
| MEDTECH ACQUISITION CORP COM CL A | $9.8m0.21% | Unchanged |
| SENIOR CONNECT ACQUISITN COR COM CL A | $9.8m0.21% | Unchanged |
| REVOLUTION HEALTHCAR AQ CORP CLASS A COM | $9.8m0.21% | Unchanged |
| PEPGEN INC PEPG | $9.5m0.20% | New |
| TURMERIC ACQUISITION CORP CL A | $7.4m0.16% | Unchanged |
| NKARTA INC NKTX | $7.4m0.16% | New |
| IGNYTE ACQUISITION CORP COM | $7.1m0.15% | Unchanged |
| APOLLO ENDOSURGERY INC COM | $6.4m0.13% | Unchanged |
| XILIO THERAPEUTICS INC COM | $6.1m0.13% | Unchanged |
| OUTSET MED INC OM | $6.0m0.13% | Unchanged |
| BENEFITFOCUS INC BNFT 1.25 12.15.23 · principal | $5.9m0.12% | New |
| GRAYBUG VISION INC COM SHS | $5.8m0.12% | Unchanged |
| AN2 THERAPEUTICS INC ANTX | $5.6m0.12% | Added +132.4k |
| NEOGENOMICS INC NEO 1.25 05.01.25 · principal | $5.4m0.11% | New |
| ORION ACQUISITION CORP COM CL A | $4.9m0.10% | Unchanged |
| NYXOAH S A NYXH | $4.2m0.09% | Unchanged |
| ORCHARD THERAPEUTICS PLC ORTX | $4.1m0.09% | Unchanged |
| ONCORUS INC COM | $4.0m0.08% | Unchanged |
| WEREWOLF THERAPEUTICS INC HOWL | $3.9m0.08% | Unchanged |
| QUANTUM SI INC QSI | $3.2m0.07% | Unchanged |
| KINNATE BIOPHARMA INC KNTE | $3.2m0.07% | Reduced -735.6k |
| ACUTUS MED INC AFIB | $3.0m0.06% | Unchanged |
Sold out since Q1 2022
| Security | Value then |
|---|---|
| BRIDGEBIO PHARMA INC BBIO 2.5 03.15.27 | $47.4m80.0m shares |
| MIRATI THERAPEUTICS INC MRTX | $22.2m270.0k shares |
| GOODRX HLDGS INC GDRX | $18.9m979.1k shares |
| NUVATION BIO INC NUVB | $18.8m3.6m shares |
| BIOCRYST PHARMACEUTICALS INC BCRX | $16.5m1.0m shares |
| OAK STR HEALTH INC OSH 0 03.15.26 | $14.3m18.0m shares |
| SPRINGWORKS THERAPEUTICS INC SWTX | $14.1m250.0k shares |
| KALVISTA PHARMACEUTICALS INC KALV | $12.2m830.5k shares |
| TERNS PHARMACEUTICALS INC | $7.0m2.3m shares |
| BENEFITFOCUS INC BNFT 1.25 12.15.23 | $6.3m6.5m shares |
| VINCERX PHARMA INC | $5.5m1.4m shares |
| CULLINAN THERAPEUTICS INC CGEM | $3.9m375.6k shares |
| NEOGENOMICS INC NEO 0.25 01.15.28 | $1.7m2.5m shares |
| AMERICAN WELL CORP | $1.6m391.1k shares |
| BIOATLA INC BCAB | $1.4m289.0k shares |
| PMV PHARMACEUTICALS INC PMVP | $10.0k470 shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| BIOGEN INC BIIB · Call | $102.0m500.0k shares | New |
Trades reported as a company insider in Q2 2022
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2022-06-06 | MIRUM PHARMACEUTICALS INC 10% owner · Through Deerfield Private Design Fund IV, L.P. | Sold | $505.5k20.2k shares |
| 2022-06-06 | MIRUM PHARMACEUTICALS INC 10% owner · Through Deerfield Healthcare Innovations Fund, L.P. | Sold | $456.8k18.3k shares |
| 2022-05-10 | PEPGEN INC 10% owner · Through Deerfield Partners, L.P. | Bought | $2.5m208.3k shares |
| 2022-05-10 | PEPGEN INC 10% owner · Through Deerfield Private Design Fund V, L.P. | Bought | $2.5m208.3k shares |